Aurinia Pharm Ord (AUPH) Stock Price, Quote & News

Company Profile

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was fou...

Industry: Biotechnology

Sector: Healthcare

Phone: 250 744 2487

Fax: 250 708 4345

Website: www.auriniapharma.com

Address:

#140, 14315 – 118 Avenue, Edmonton, Canada

ResearchGroupChart Apr. 9 at 9:09 AM

$AUPH a biotech firm named Aurinia Pharmaceuticals

0 · Reply

DragonAlgo Apr. 9 at 7:04 AM

🐉 $AUPH CALL — DragonAlgo® Signal Contract: AUPH CALL Expiry: 2026-04-17 | Strike: $17.00 | Type: CALL Option Plan (premium): Entry: $0.09 Stop: $0.06 TP1: $0.12 TP2: $0.15 TP3: $0.22 🔗 https://dragonalgo.com

0 · Reply

Yarrow Apr. 9 at 5:04 AM

$AUPH 52 Week HIGH close tomorrow please. Or at least by Friday.

0 · Reply

Theobviouschoice Apr. 9 at 1:03 AM

$AUPH Big buy AH $1.85M

0 · Reply

jdoldnumber7 Apr. 8 at 11:57 PM

$AUPH Tomorrow will be better!

0 · Reply

ultistock Apr. 8 at 9:58 PM

$AUPH Hoping for some good news tomorrow, because, why not? Eventually they do have to tell us the plan for Aritinicept, right? Realistically I wonder when that day will be when they are forced to give us the details?

1 · Reply

VSTN Apr. 8 at 8:03 PM

$AUPH Not great, but it’s a step forward

0 · Reply

BX_MoneyMakr Apr. 8 at 7:31 PM

$AUPH 😞

0 · Reply

pikus Apr. 8 at 6:32 PM

$AUPH Auph only stock down in my portfolio.

1 · Reply

Amber_Turd Apr. 8 at 6:28 PM

$AUPH looks like a retreat down to the 15.00 range again with no further news

1 · Reply

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

KZR

Mar 23, 2026, 11:00 AM EDT - 16 days ago

MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition

Mar 23, 2026, 10:26 AM EDT - 16 days ago

Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning

Mar 23, 2026, 8:00 AM EDT - 16 days ago

Aurinia Announces Management Transition

Feb 26, 2026, 4:06 PM EST - 5 weeks ago

Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets

Feb 26, 2026, 6:00 AM EST - 5 weeks ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

Feb 19, 2026, 6:00 AM EST - 6 weeks ago

Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

Nov 4, 2025, 6:00 AM EST - 5 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress

Nov 3, 2025, 6:00 AM EST - 5 months ago

Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025

Oct 15, 2025, 6:00 AM EDT - 6 months ago

Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

Sep 29, 2025, 8:27 PM EDT - 6 months ago

Aurinia Responds to Now Retracted LinkedIn Post

Jul 31, 2025, 6:00 AM EDT - 8 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025

Jul 22, 2025, 6:00 AM EDT - 9 months ago

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025

Jun 30, 2025, 6:00 AM EDT - 10 months ago

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

Jun 29, 2025, 5:00 PM EDT - 10 months ago

Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025

May 22, 2025, 6:00 AM EDT - 11 months ago

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

May 12, 2025, 12:56 PM EDT - 11 months ago

Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance

May 12, 2025, 6:00 AM EDT - 11 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

May 5, 2025, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

Apr 30, 2025, 6:00 AM EDT - 1 year ago

Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

Apr 29, 2025, 6:00 AM EDT - 1 year ago

ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting

Feb 27, 2025, 2:11 PM EST - 1 year ago

Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations

Feb 27, 2025, 6:00 AM EST - 1 year ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

Feb 20, 2025, 4:05 PM EST - 1 year ago

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Nov 18, 2024, 5:53 PM EST - 1 year ago

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Nov 15, 2024, 6:00 AM EST - 1 year ago

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Nov 14, 2024, 6:00 AM EST - 1 year ago

Aurinia to Participate in Jefferies London Healthcare Conference

Nov 7, 2024, 6:10 AM EST - 1 year ago

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

Nov 7, 2024, 6:00 AM EST - 1 year ago

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

Oct 11, 2024, 6:00 AM EDT - 1 year ago

Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024

Sep 24, 2024, 8:10 AM EDT - 1 year ago

Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis

Sep 13, 2024, 6:00 AM EDT - 1 year ago

Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Aurinia Announces Board Restructuring

Sep 5, 2024, 6:00 AM EDT - 1 year ago

Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

Aug 28, 2024, 6:00 AM EDT - 1 year ago

Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board

Aug 1, 2024, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results

Jul 19, 2024, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024

Jul 11, 2024, 3:27 PM EDT - 1 year ago

ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders' Voices Expressed at the AGM

Jul 2, 2024, 6:00 AM EDT - 1 year ago

Aurinia to Participate in Upcoming Investor Healthcare Conferences

Jun 14, 2024, 12:16 PM EDT - 1 year ago

Aurinia Announces 2024 Annual General Meeting Results

Jun 5, 2024, 6:00 AM EDT - 2 years ago

Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024

Jun 4, 2024, 5:30 PM EDT - 2 years ago

Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce

Jun 3, 2024, 6:30 PM EDT - 2 years ago

Aurinia Provides Update on Proxy Statement

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Aurinia Pharmaceuticals Shareholder Urges Fellow Shareholders to Withhold Support for CEO Peter Greenleaf

May 30, 2024, 6:00 AM EDT - 2 years ago

Aurinia Will Attend 2024 Jefferies Global Healthcare Conference

May 14, 2024, 6:00 AM EDT - 2 years ago

Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024

May 9, 2024, 6:00 AM EDT - 2 years ago

Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024

ResearchGroupChart Apr. 9 at 9:09 AM

$AUPH a biotech firm named Aurinia Pharmaceuticals

0 · Reply

DragonAlgo Apr. 9 at 7:04 AM

0 · Reply

Yarrow Apr. 9 at 5:04 AM

$AUPH 52 Week HIGH close tomorrow please. Or at least by Friday.

0 · Reply

Theobviouschoice Apr. 9 at 1:03 AM

$AUPH Big buy AH $1.85M

0 · Reply

jdoldnumber7 Apr. 8 at 11:57 PM

$AUPH Tomorrow will be better!

0 · Reply

ultistock Apr. 8 at 9:58 PM

1 · Reply

VSTN Apr. 8 at 8:03 PM

$AUPH Not great, but it’s a step forward

0 · Reply

BX_MoneyMakr Apr. 8 at 7:31 PM

$AUPH 😞

0 · Reply

pikus Apr. 8 at 6:32 PM

$AUPH Auph only stock down in my portfolio.

1 · Reply

Amber_Turd Apr. 8 at 6:28 PM

$AUPH looks like a retreat down to the 15.00 range again with no further news

1 · Reply

jrobbins64 Apr. 8 at 4:57 PM

$AUPH

1 · Reply

jdoldnumber7 Apr. 8 at 4:53 PM

$AUPH Get your head out of your ass and let's go.. This is as easy as a day can be......GREEN!

1 · Reply

SCCT2FL Apr. 8 at 4:45 PM

$AUPH ok lunch is wrapping up, let's get back to push this into close

0 · Reply

SweetHome Apr. 8 at 4:38 PM

$AUPH This would have been a nice day for Tang&Co to have some good news teed up for an early PR.

0 · Reply

Auphiliate Apr. 8 at 4:01 PM

$AUPH Hey Tang! You’re going the wrong way! 😂

0 · Reply

Bustingline Apr. 8 at 3:37 PM

$AUPH Still here waiting and Praying 🙏.

0 · Reply

Martinsucks Apr. 8 at 3:37 PM

$AUPH when is a realistic date for a buyout? Tang bought a month ago so another 2 to 4 months for him to be safe rather then sorry. When do you guys think? I may go all in every Friday afternoon going into weekend for Monday merger.

1 · Reply

Auphiliate Apr. 8 at 2:34 PM

$AUPH Should we be concerned with ongoing patent delays @US_Bull? 🤔

1 · Reply

jdoldnumber7 Apr. 8 at 2:33 PM

$AUPH Kinda disappointing out of gate. 145K shares traded first hour and SP up .12 cents. Like to think afternoon will be more lively...

0 · Reply

pikus Apr. 8 at 2:25 PM

$AUPH added a bit more

0 · Reply

Send_IT_or_stepaside Apr. 8 at 1:30 PM

$AUPH gap and go you !!!

0 · Reply

DragonAlgo Apr. 8 at 1:18 PM

🐉 $AUPH CALL — DragonAlgo® Signal Contract: AUPH CALL Expiry: 2026-04-17 | Strike: $16.00 | Type: CALL Option Plan (premium): Entry: $0.50 Stop: $0.36 TP1: $0.65 TP2: $0.85 TP3: $1.20 Risk preset by model constraints. 🔗 https://dragonalgo.com

0 · Reply

Market Cap	2.10B
Revenue (ttm)	283.06M
Net Income (ttm)	287.20M
EPS (ttm)	N/A
PE Ratio	19.75
Forward PE	19.21
Profit Margin	101.46%
Debt to Equity Ratio	0.00

Volume	843,900
Avg Vol	1,058,920
Day's Range	N/A - N/A
Shares Out	132.97M
Stochastic %K	83%
Beta	1.51
Analysts	Sell
Price Target	$17.00